Page last updated: 2024-11-04

o-methyltyramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

o-Methyltyramine (OMT) is a trace amine that is a metabolite of tyramine. It is found in the brain and other tissues. OMT is a substrate for the enzyme monoamine oxidase (MAO), and it is also a potent inhibitor of the dopamine transporter. OMT has been shown to have a variety of pharmacological effects, including anxiolytic, antidepressant, and stimulant effects. OMT is also a potent neurotoxin, and it has been implicated in the pathogenesis of Parkinson's disease. OMT is studied because of its potential therapeutic effects, as well as its potential role in the development of neurological disorders.'

O-methyltyramine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-methoxyphenylethylamine : A primary amino compound consisting of ethylamine having a 4-methoxyphenyl substituent at the 2-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4657
CHEMBL ID101036
CHEBI ID266039
SCHEMBL ID4634
SCHEMBL ID4779445
MeSH IDM0052419

Synonyms (79)

Synonym
2-(4-methoxyphenyl)ethan-1-amine
4-methoxyphenylethylamine
4-methoxybenzeneethanamine
wln: z2r do1
4-methoxy-2-phenethylamine
4-methoxy-.beta.-phenylethylamine
2-(4-methoxyphenyl)ethylamine
p-methoxyphenylethylamine
usaf el-52
phenethylamine, p-methoxy-
2-(p-methoxyphenyl)ethylamine
tyramine, o-methyl-
homoanisylamine
nsc-43687
nsc43687
p-methoxyphenethylamine
4-methoxyphenethylamine
o-methyltyramine
4-methoxy-beta-phenylethylamine
einecs 200-245-5
brn 0508967
nsc 43687
inchi=1/c9h13no/c1-11-9-4-2-8(3-5-9)6-7-10/h2-5h,6-7,10h2,1h
55-81-2
2-(4-methoxyphenyl)ethanamine
benzeneethanamine, 4-methoxy-
para-methoxyphenylethylamine
4-methoxyphenethylamine, >=98%
NCGC00163353-01
zhh ,
bdbm50240697
2-(4-methoxy-phenyl)-ethylamine
CHEMBL101036 ,
4-(2-aminoethyl)anisole
M0795
chebi:266039 ,
AKOS000119749
A8057
4-13-00-01789 (beilstein handbook reference)
unii-uce8p23xwf
uce8p23xwf ,
2-(4-methoxyphenyl)ethylammonium;2-(4-methoxy-phenyl)-ethylamine
A830820
4-methoxy-2-phenylethylamine
FT-0618946
STL371947
BBL027694
SCHEMBL4634
4-methoxylphenylethylamine
{2-[4-(methyloxy)phenyl]ethyl}amine
2-(4-methoxyphenyl) ethylamine
4-methoxyphenethyl amine
2-(4-methoxy-phenyl)-ethyl-amine
2-(4-methoxyphenyl)ethaneamine
p-methoxyphenethyl amine
2-( 4-methoxyphenyl)ethylamine
2-(4-methoxy-phenyl)ethylamine
4-methoxybenzenethanamine
4-methoxyphenethyl-amine
para-methoxyphenethylamine
2-(4-methoxyphenyl)-ethylamine
4-methoxy-phenethylamine
4-methoxyphenylethyl amine
4-methoxybenzylmethylamine
DTXSID6058764
mfcd00008192
SCHEMBL4779445
W-105546
2-(4-methoxyphenyl)ethanamine #
F2190-0399
4-methoxy-benzeneethanamine
10.14272/LTPVSOCPYWDIFU-UHFFFAOYSA-N.1
doi:10.14272/ltpvsocpywdifu-uhfffaoysa-n.1
STR05874
AMY41549
Q27225715
EN300-20025
SY001720
Z104476454
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Kd7.94330.00042.58328.5114AID6406
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Kd7.94330.00012.62198.5114AID6406
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Kd7.94330.00012.29338.5114AID6406
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Kd7.94330.02342.74218.5114AID6406
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Kd7.94330.02342.74218.5114AID6406
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Kd7.94330.02342.74218.5114AID6406
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Kd7.94330.00042.47358.5114AID6406
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)Kd7.94330.02342.74218.5114AID6406
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Kd7.94330.00012.70068.5114AID6406
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)Kd7.94330.02342.74218.5114AID6406
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)Kd7.94330.02342.74218.5114AID6406
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)Kd7.94330.00082.62148.5114AID6406
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)Kd7.94330.02342.74218.5114AID6406
Trace amine-associated receptor 1Homo sapiens (human)EC50 (µMol)5.98000.01501.41437.1900AID341210
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)Kd7.94330.00082.62148.5114AID6406
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityTrace amine-associated receptor 1Homo sapiens (human)
trace-amine receptor activityTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID19263Log value of hallucinogenic activity was determined1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
AID6406Affinity against 5-hydroxytryptamine receptors in rat fundus model1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Serotonin receptor affinities of psychoactive phenalkylamine analogues.
AID341210Agonist activity at human trace amine associated receptor 1 expressed in RD-HGA16 CHO-K1 cells coexpressed with Galpha16 protein assessed as internal calcium mobilization by calcium 3 assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity correlations for beta-phenethylamines at human trace amine receptor 1.
AID88883Hallucinogenic activity i.e; ratio of effective dose of mescaline to the effective dose in human1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Structure-activity correlations for psychotomimetics. 1. Phenylalkylamines: electronic, volume, and hydrophobicity parameters.
AID1131957Hallucinogenic activity in human relative to mescaline1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Structure-activity studies on hallucinogenic amphetamines using molecular connectivity.
AID341211Agonist activity at human trace amine associated receptor 1 expressed in RD-HGA16 CHO-K1 cells coexpressed with Galpha16 protein assessed as internal calcium mobilization by calcium 3 assay relative to 2-phenylethanamine2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity correlations for beta-phenethylamines at human trace amine receptor 1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (41.18)18.7374
1990's1 (5.88)18.2507
2000's4 (23.53)29.6817
2010's2 (11.76)24.3611
2020's3 (17.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.93 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]